Antibiotics Market Report 2026

The antibiotics market size has grown steadily in recent years. It will grow from $89.16 billion in 2025 to $93.37 billion in 2026 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to rising incidence of bacterial infections, increasing demand for broad-spectrum antibiotics, growth of hospital infrastructure, advances in generic drug manufacturing, government health initiatives.

The antibiotics market size is expected to see strong growth in the next few years. It will grow to $115.82 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to increasing antibiotic resistance, rising focus on precision medicine, growth in personalized healthcare, technological advancements in drug delivery, expansion of emerging markets. Major trends in the forecast period include antibiotic resistance management, development of novel antibiotics, personalized antibiotic therapy, expansion of hospital and retail distribution networks, increase in outbreak and infection control measures.

The increasing incidence of bacterial infections is anticipated to fuel the expansion of the antibiotics market in the coming years. Bacterial infections, which are caused by harmful bacteria, can result in severe diseases such as cholera, typhoid, and sepsis, all of which require effective antibiotic therapy to avoid serious complications and reduce mortality. Antibiotics play a crucial role in both the treatment and prevention of bacterial illnesses by inhibiting the growth and spread of bacteria. For example, in December 2023, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that as of 15 November 2023, preliminary data from Member States indicated that the number of reported cases had surpassed those recorded in 2022, with more than 610,000 cases and 3,500 deaths, leading to a case fatality rate of 0.6%. As a result, the growing prevalence of bacterial infections is contributing to the growth of the antibiotics market.

Leading companies operating in the antibiotics market are increasingly adopting strategic partnerships to improve access to innovative antibacterial therapies. Strategic partnerships involve collaborations in which companies combine their respective strengths, expertise, and resources to achieve shared goals and long-term success. For instance, in June 2024, Orchid Pharma Limited, an India-based pharmaceutical company, announced a partnership with Cipla Limited, another India-based pharmaceutical company, to effectively launch and distribute Cefepime-Enmetazobactam across India. This collaboration brings together Orchid Pharma’s advanced drug development expertise with Cipla’s broad distribution capabilities to introduce Cefepime-Enmetazobactam, an antibiotic approved for the treatment of complicated urinary tract infections and pneumonia. The initiative aims to expand access to this essential medication nationwide while addressing the escalating issue of antimicrobial resistance and encouraging responsible antibiotic use among healthcare professionals.

In September 2023, Gurnet Point Capital, a US-based healthcare investment firm, together with Novo Holdings A/S, a Denmark-based investment company, acquired Paratek Pharmaceuticals, Inc. for $462 million. Through this acquisition, the investors seek to reinforce efforts to combat antimicrobial resistance by gaining control of Paratek’s flagship product, NUZYRA (omadacycline), a once-daily antibiotic used to treat community-acquired bacterial infections. Paratek Pharmaceuticals, Inc. is a US-based company specializing in the manufacture of antibiotic medications.

Major companies operating in the antibiotics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb (BMS), AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim, Viatris Inc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Sun Pharmaceutical Industries Limited, Cipla Ltd., Ferring Pharmaceuticals, Hikma Pharmaceuticals plc, Lupin Pharmaceuticals Inc., Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Limited, Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Nabriva Therapeutics Plc.

North America was the largest region in the antibiotics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibiotics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the antibiotics market by increasing the cost of imported raw materials, pharmaceutical intermediates, and active pharmaceutical ingredients (APIs), which has led to higher production costs and disrupted supply chains. Hospital and retail pharmacy segments in regions like Asia-Pacific and Europe, which rely heavily on imports, are most affected. However, tariffs have encouraged local manufacturing investments and innovation in cost-efficient production methods, creating opportunities for domestic producers.

The antibiotics market research report is one of a series of new reports that provides antibiotics market statistics, including antibiotics industry global market size, regional shares, competitors with a antibiotics market share, detailed antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the antibiotics industry. This antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Antibiotics are a group of medications that function by killing bacteria or preventing their growth, thereby assisting the body’s immune system in clearing infections. They are used to treat a wide range of infections caused by bacterial pathogens.

The major drug classes of antibiotics include penicillin, cephalosporins, aminoglycosides, tetracyclines, macrolides, fluoroquinolones, sulfonamides, and others. Penicillin is a class of antibiotics originally derived from the Penicillium fungus. The different spectrums of activity include broad-spectrum and narrow-spectrum antibiotics. These drugs are administered through various routes, such as oral, intravenous, and other methods, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. They are used across multiple applications, including skin infections, respiratory infections, urinary tract infections, septicemia, ear infections, gastrointestinal infections, and others.

The antibiotics market consists of sales of Glycopeptides, Clindamycin, and Quinolones. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.